Flibanserin CAS: 167933-07-5

Female Sex Enhancement Powder Women Sexual Desire Disorder Flibanserin CAS: 167933-07-5 Molecular formula: C20H21F3N4O Molecular weight: 390.4 purity: 99% Appearance: White powder Grade: Pharmaceutical grade Usage:adrug being studied as a non-hormonal treatment for pre-menopausal women with hypoactive sexual desire disorder Catagory: Pharmaceutical raw material female sex enhance Introduction:HSDD is the most commonly reported form of female sexual dysfunction.

HSDD is defined as a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty, and which is not better accounted for by a medical, substance-related, psychiatric (e.g., depression) or other sexual condition.

The cause of HSDD is believed to involve a multitude of social, psychological and biological factors and may be attributed to a complex interplay of these factors. Applications: A new drug designed to boost sexual desire in women is controversial for some and eagerly awaited by others, but it's hit a potentially serious snag.

The drug didn't boost women's desire any more than a placebo in two clinical trials. The Food and Drug Administration posted the clinical trial results on its website today in advance of a committee meeting on Friday, when a panel of experts will vote whether or not to recommend approval of the drug called flibanserin.

(The FDA usually follows the recommendations of its expert panels. ) Although there was a slight increase in the number of sexually satisfying events flibanserin users had each month, the FDA staff who reviewed the results said the so-called response rate isn't "particularly compelling.

It's called the "little pink pill, " a tiny tablet that could have a huge impact on treating female sexual dysfunction. If it's approved, it would become the first drug of its kind on the market.